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INTRODUCTION
Cervical cancer is the third most diagnosed cancer
and the fourth cause of female mortality world-
wide. From 13 pathology center in Indonesia, cer-
vical cancer is the first rank among all cancers
(23,4% of 10 most common cancers in men and
women). Data from university hospitals in 2007
stated that cervical cancer is the most gynecology
Abstract
Objective: To evaluate the theurapeutic response and acute toxicity
of neoadjuvant chemotherapy between the combination of Platinum
and Ifosfamide, and the combination of Platinum, Vincristine and
Bleomycin in Cervical Carcinoma Stage IB2 and then continued with
radical hysterectomy and pelvic lymphadenectomy.
Method: Thirteen samples received neoadjuvant chemotherapy of
Platinum and Ifosfamide and 17 samples received neoadjuvant che-
motherapy of Platinum, Vincristine and Bleomycin, after receiving
the neoadjuvant chemotherapy, clinically complete response sam-
ples underwent radical hysterectomy and pelvic lymphadenectomy
(PI VS PVB = 3 VS 1). Histopathology examination was performed to
evaluate the presence of malignant viable cells at the cervix, pelvic
lymph node metastasis and parametrium metastasis. Acute toxicity
evaluation was performed based on gastrointestinal, genitourina-
rius and hematology sign and symptom.
Result: Theurapeutic response of PI is 1.12 higher than PVB
(p>0.05). Subanalysis of group response of PI is 1.962 higher than
PVB. PI and PVB have the same risk to have pelvic lymph node me-
tastasis, but not parametrial metastasis. There were no differences
in terms of the risk of gastrointestinal, genitourinarius and hema-
tologic toxicity between PI and PVB.
Conclusion: There was no statistical difference in clinical and
pathological response, and also in acute toxicity between the two
combination (p>0.05).
[Indones J Obstet Gynecol 2016; 1: 47-51]
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Abstrak
Tujuan: Untuk mengevaluasi respons terapi dan toksisitas akut pada
kasus karsinoma serviks stadium IB2 yang mendapatkan kemoterapiajuvan kombinasi platinum dan ifosfamide dan kombinasi platinum,
vincristine dan bleomycin, yang dilanjutkan dengan histerektomi ra-
dikal dan diseksi kelenjar getah bening.
Metode: Sebanyak 13 sampel mendapatkan kemoterapi neoajuvan
kombinasi platinum dan ifosfamide dan sebanyak 17 sampel menda-patkan kemoterapi neoajuvan kombinasi platinum, vincristine dan
bleomycin. Pasca pemberian kemoterapi neoajuvan, sampel denganrespons komplit, dilanjutkan dengan tindakan histerektomi radikal
dan diseksi masing-masing kelenjar getah bening pelvis (PI VS PVB =
3 VS 1). Penilaian histopatologi dilakukan untuk penilaian adanya ma-lignant viable cell di masa tumor, metastasis kelenjar getah bening
pelvis dan parametrium. Penilaian toksisitas akut dilakukan pada gas-
trointestinal, genitourinarius dan hematologi.
Hasil: Respons terapi kombinasi PI adalah 1,12 kali lebih besar diban-dingkan dengan kombinasi PVB (p>0,05). Subanalisis respons kelompok
terapi kombinasi PI adalah sebesar 1,962 kali lebih dibandingkan de-
ngan kombinasi PVB (p>0,05). Kombinasi PI mempunyai risiko yangsama dengan kombinasi PVB dalam hal ditemukannya metastasis ke-
lenjar getah bening pelvis, tetapi tidak untuk metastasis pada para-
metrium. Pada pemberian kemoterapi kombinasi PI, tidak ditemukanperbedaan risiko terjadinya toksisitas gastrointestinal, genitourinarius
dan hematologi selama terapi dibandingkan dengan kombinasi PVB.
Kesimpulan: Tidak didapatkan perbedaan yang bermakna pada res-
pons terapi secara klinis dan histopatologi, juga pada toksisitas akutantara kedua kombinasi (p>0,05).
[Maj Obstet Ginekol Indones 2016; 1: 47-51]
Kata kunci: karsinoma serviks stadium IB2, kemoterapi neoajuvan,respons, toksisitas akut
Correspondence: Kartiwa H Nuryanto. Department of Obstetrics and Gynecology, Faculty of Medicine University of Indonesia, Jakarta.
Telephone: 0811-1488028; Email: kartiwa_h_nuryanto@yahoo.com
Vol 4, No 1
January 2016 Theurapeutic response of neoadjuvant chemotherapy  47
cancer, followed by ovarian, endometrial, vulva and
vaginal cancer.1,2
A study on cervical cancer at Dr. Cipto Mangun-
kusumo Hospital Jakarta stated that 5 years sur-
vival rate of cervical cancer stage I, II, III and IV is
50%, 40%, 20% and 0%. Marisa et. al3 in 2013
stated that 1-survival rate of cervical cancer stage
IB-IIA that underwent radical hysterectomy and
pelvic lymphadenectomy at RSCM is 96%, while 2-
years is 90%, 3-years is 83%, 4-years is 73% and
5-years is 71%.
In stage IB2, the tumor size is bigger than 4 cm
which makes it the most important predictor for
local recurrence and smaller survival rate. The big
tumor mass increases the risk of stromal invasion
that leads to higher risk of lymph node metastasis.
The neoadjuvant chemotherapy hopefully will de-
creased the size of the tumor so that the shrinkage
of the tumor mass will decrease the risk of lymph
node metastasis.4
Management for cervical cancer stage IB2 is still
debatable among oncologists, as some prefer to
have surgery while others have radiation/chemo-
radiation as the main management. Neoadjuvant
chemotherapy before definitive management has
been an option, Kim H.S. et al5 stated that even
neoadjuvant chemotherapy has decreased the rate
of adjuvant radiation after surgery by decreasing
the tumor mass and the risk of lymph node metas-
tasis, but it does not improve the survival rate com-
pared to primary radical hysterectomy. Study on
neoadjuvant chemotherapy of Platinum, Vincris-
tine and Bleomycine on cervical cancer stage IB2
stated that it gives better response prior the sur-
gery, that are 12% for clinical complete response
and 81% for 2-years-disease-free-survival rate.6-10
González-Martín et. al.11 also stated in a meta
analysis that neoadjuvant chemotherapy followed
by surgery is better than radiation only in terms of
overall survival. Hwang YY et. al.12 reported his
study on 10-years-observation of 80 patients with
stage IB-IIB cervical cancer with tumor size of 4
cm after neodjuvant chemotherapy with Cisplatin,
Bleomycine and Vincristine continued by radical
hysterectomy, that there were 75 patients with tu-
mor shrinkage, with 5 and 10 years-survival rate
of 82% and 79,4%. Hutapea et. al.13 in 2011 re-
ported 10 negative clinical response and 7 positive
clinical response (n=17) based on RECIST with
neoadjuvant chemotherapy (Cisplatin, Vincristine
and Bleomycine). The positive clinical response
consists of 2 clinical complete response and 5 clini-
cal partial response. All clinical complete response
revealed pathological complete response as well.
Neoadjuvant chemotherapy of Cisplatin and Ifosfa-
mide was also reported by Zanetta et. al.14 on cer-
vical cancer stage IB2, with significant response
and overall response rate of 84% (CI 95% = 68%-
94%) and with tolerable toxicity.
At RSCM, neoadjuvant chemotherapy has been
used as part of cervical-cancer-stage-IB2 manage-
ment. The combination of the chemotherapy regi-
mens are Platinum-Vincristine-Bleomycine (which
is used earlier) and Platinum-Ifosfamide. This stu-
dy will evaluate the response of both combination
at RSCM, based on the clinical response, patholo-
gical response and toxicity.
METHODS
The study is an ambispective cohort which took
place from April 2013 - August 2014 at The Divison
of Oncology Gynecology, Department of Obstetrics
and Gynecology, Medical Faculty University of In-
donesia, Dr. Cipto Mangunkusumo Hospital Jakarta.
The study population is cervical cancer stage IB2
who received neoadjuvant chemotherapy, either
combination of platinum, vincristine and bleomy-
cine, or combination of platinum and ifosfamide,
the followed by radical hysterectomy and pelvic
lymphadenectomy. Total samples needed were 62
samples for each group.
Since ambispective cohort was used as study de-
sign, retrospective and prospective samples were
used. Inclusion criterias include complete medical
records, cervical cancer stage IB2 that has been
confirmed histopathologically and has completed
3-cycle of neoadjuvant chemotherapy, either with
combination of PVB or PI, followed by radical hys-
terectomy and pelvic lymphadenectomy, and pa-
tients who agreed to participate in the study. Ex-
clusion criteria include incomplete medical re-
cords, patients with pelvic and/or paraaortic
lymphadenectomy based on imaging, patients with
lung or bone or liver metastasis based on imaging,
patients who did not complete 3-cycle neoadjuvant
chemotherapy, patients with other cancers and
patients who refused to participate in the study.
All samples that fulfilled inclusion and exclusion
criteria, were given 3-cycle neoadjuvant chemo-
therapy. Assessment of clinical response was per-
formed 3 weeks after the last neoadjuvant chemo-
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therapy at the latest. Samples with clinical com-
plete response then underwent radical hysterec-
tomy and pelvic lymphadenectomy. Histopatholo-
gical examination of surgical specimen was per-
formed to evaluate the malignant viable cells at the
tumor mass, lymph node metastasis and parame-
trial metastasis. Patients with malignant viable
cells at the tumor mass, lymph node metastasis
and parametrial metastasis, then received adjuvant
radiation/chemoradiation.
RESULTS
There were 13 samples that received combination
of platinum and ifosfamide as neoadjuvant che-
motherapy dan 17 samples that received combi-
nation of platinum, vincristine and bleomycine as
neoadjuvant chemotherapy.
The age, education and profession distribution
is found at Table 1. The most age distribution is
38-48 years, 8 samples (61.5%) from combination
of PI and 10 samples (58.9%) from combination of
PVB. There were 4 samples (30.8%) of PI combi-
nation and 7 samples (41.1%) of PVB combination
at the age distribution of 49-59 years.
The education distribution showed that the
most distribution is high school for combination of
PI (38.4%) and elementary for combination of PVB
(53%).
The chemotherapy response is divided into posi-
tive and negative response, in which positive res-
ponse consists of clinical complete response and
partial response, while negative response consists
of stable disease and progressive disease. The res-
ponse distribution can be seen on Table 2.
There were 3 (23.1%) clinical complete res-
ponse of PI combination and 2 (11.8%) clinical
complete response of PVB combination. Subana-
lysis was performed to evaluate the response of
clinical complete response and nonclinical complete
response, which consists of clinical partial res-
ponse, stable disease and progressive disease (PI
vs PVB = 3 : 10 vs 2 : 15).
The clinical complete response samples were
then scheduled for radical hysterectomy and pelvic
lymphadenectomy. Surgery was performed to all PI
samples and only 1 PVB sample due to respect-
ability reason (PI vs PVB = 3 vs 1).
Table 3. Distribution of Histopathological Result
Chemotherapy MVC LNM PM 
PI combination (n=3) 3 (100%) 3 (100%) 0 (0%)
PVB combination (n=1) 1 (100%) 1 (100%) 1 (100%)
MVB: Malignant Viable Cells; LNM: Lymph node metastasis;PM: Parametrialmetastasis
Table 1. Demographic Data and Cancer Stage
Demographic Data Combination of PI(n=13) %
Combination of PVB
(n=17) %
Age (years)
38 - 48 8 61.5 10 58.9
49 - 59 4 30.8 7 41.1
≥ 60 1 7.7 0 0
Education
Undergraduate 2 15.4 1 5.9
Elementary 4 30.8 9 53.0
Junior High 1 7.7 3 17.6
Senior High 5 38.4 4 23.5
Bachelor 1 7.7 0 0
Table 2. Distribution of Response based on Tumor Size after Neoadjuvant Chemotherapy (RECIST)
Response Complete Partial Stable disease Progressive
PI combination (n=13) 3 (23,1%) 3 (23,1%) 2 (15,4%) 5 (38,4%)
PVB combination (n=17) 2 (11,8%) 5 (29,4%) 1(5,9%) 9 (52,9%)
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Based on histopathological examination, malig-
nant viable cells and positive lymph nodes metas-
tasion were found in all complete response sam-
ples. Parametrial metastasis occurred only in com-
bination of PVB. See Table 3.
Acute toxicity was divided into 3 categories,
which are gastrointestinal, genitourinary and he-
matology. All samples in both combination re-
ported abdominal discomfort and nausea without
the need of medical management. Genitourinary
toxicity was not found at PI samples but found at
2 (11,7%) PVB samples. Hematology toxicity, that
is Hb level 9.5-10.9 gr% or leucocyte < 3.900/m3,
was reported at 4 (30.8%) PI samples and 5
(29.4%) PVB samples. See Table 4.
Table 4. Distribution of Acute Toxicity
Toxicity Gastrointes­
tinal 
Genitourina
ry
Hematology
Combination of
PI (n=13)
13 (100%) 0 (0%) 4 (30.8%)
Combination of
PVB (n=17)
17 (100%) 2 (11.8%) 5 (29.4%)
DISCUSSION
Total samples collected were 13 samples for PI
combination and 7 samples for PVB combination.
As the samples were not able to reach the minimal
amount, it was realized that the power of the study
might be less and be considered as a preliminary
report.
The mean and median of age distribution for PI
combination are 47.3 and 46 years old, while for
PVB combination are 47.5 and 47 years old. The
age distribution showed similarity between 2
groups. Data from INASGO 2009-2013 stated that
the most age distribution is 36-45 years old, while
in the study is 38-48 years old, so that it also
showed similarity in the age distribution.
The main purpose of giving neoadjuvant chemo-
therapy is to decrease the tumor size to improve
the respectability and decrease the risk factors for
recurrency. Li et al.15 stated that neoadjuvant che-
motherapy would decrease the risk of LVSI and
stromal infiltration which finally would decrease
the risks of lymph node metastasis.
Recist was used to evaluate the clinical response,
which was performed 3 weeks after the last course
of neoadjuvant chemotherapy. The response was
divided into positive and negative response. The
positive response was then divided into complete
response and partial response, while the negative
response was divided into stable and progressive
disease. The RR of positive and negative response
is 1.2 (p>0.05). It showed that PI combination has
a better chance to give positive response compared
to PVB combination, although the p value showed
insignificancy of the chance. Subanalysis RR was
also calculated to evaluate the relation between the
complete response and the group of partial res-
ponse, stable and progressive disease. The RR is
1.96 (p>0.05), which showed that PI combination
has also a better chance compared the PVB combi-
nation. The result of p value, which is > 0.05,
showed that the chance although is 1.96 is statis-
tically insignificant. The RRs could be considered
as preliminary RRs in evaluating the clinical res-
ponse of PI and PVB combination. Both insignifi-
cant values for both RRs might be due to the num-
ber of samples collected, so that further study with
more samples is needed. The insignificant result
might also due to bio-molecular reasons which in
this study was not analyzed. Colombo et al16, in a
critical review stated that there was not enough
data to show the superiority of each combination
as neoadjuvant chemotherapy for cervical cancer
before the definitive procedure, so a study to evalu-
ate the chemotherapy combination is needed.
In histopathological response, the main purpose
is to evaluate the presence of malignant viable cell,
lymph node and parametrial metastasis. The histo-
pathological response should correspond to the
clinical response. The categories used are17 : Patho-
logical complete response, in which there is no
more residual or viable tumor at the surgery speci-
men, tumor mass and/or lymph node (T0N0 M0).
Near-complete or Microscopic Response, in which
one or more focuses or malignant viable cells
measuring less than 1 mm at the surgery specimen,
tumor mass and/or lymph node. Pathological par-
tial response, in which the residual mass measur-
ing more than 1 mm at the surgery specimen, tu-
mor mass and/or lymph node.
As it was mentioned that all clinical complete
response of PI combination (n=3) underwent sur-
gery while only 1 of PVB combination. The RR of
malignant viable cell at the tumor mass and lymph
node metastasis are 1 (p value can not be calcu-
lated because there was no comparison), which
showed that there was no difference in the chance
of pathological complete response between PI and
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PVB combination in tumor mass and pelvic lymph
node. The RR of parametrial metastasis is 4
(p>0.05), which not only showed that there was a
positive association between the neoadjuvant
chemotherapy and the parametrial metastasis, but
also showed that PI combination has a better
chance to eliminate the risk of parametrial metas-
tasis compared to PVB combination.
These data showed that clinical complete res-
ponse does not correspond to pathological com-
plete response in the presence of malignant viable
cell and lymph node metastasis. Pathological com-
plete response should more be understood and
taken into consideration as it plays important role
in recurrency and survival.
RR for toxicity distribution of gastrointestinal is
1 (p value can not be calculated because there was
no comparison) and of hematology is 1.04 (p>0.62),
while of genitourinarius is 0 (p>0.05). It showed
that there was no difference in acute gastrointesti-
nal and hematology toxicity between PI and PVB
combination, while there was no risk of genitouri-
narius toxicity in PI combination compared to PVB
combination. The insignificancy of all correlation
might be due insufficient amount of samples in both
groups.
All samples with malignant viable cell and lymph
node metastasis received adjuvant radiation/
chemoradiation.
CONCLUSIONS
Clinical and histopathological response and also
the acute toxicity of PI and PVB combination as
neoadjuvant chemotherapy does not differ signifi-
cantly. The clinical response does not correspond
to histopathological response, where it should be
taken for consideration to evaluate the risk of re-
currency and survival. Further study should be
done not only to evaluate both clinical and histopa-
thological response of neoadjuvant chemotherapy
of PI and PVB combination, but also to evaluate
which combination among several combination
used by oncologist give a better result.
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